Home Clinical Applications of the 2nd Generation Assay for Anti-TSH Receptor Antibodies in Graves' Disease. Evaluation in Patients with Negative 1st Generation Test
Article
Licensed
Unlicensed Requires Authentication

Clinical Applications of the 2nd Generation Assay for Anti-TSH Receptor Antibodies in Graves' Disease. Evaluation in Patients with Negative 1st Generation Test

  • Luca Giovanella , Luca Ceriani and Silvana Garancini
Published/Copyright: June 1, 2005
Become an author with De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 39 Issue 1

Abstract

Detection of autoantibodies to the thyrotropin receptor by radioreceptor assays is largely requested in clinical practice for the diagnosis of Graves' disease and its differentiation from diffuse thyroid autonomy. Additionally, thyrotropin receptor antibodies (TRAb) measurement during antithyroid drug treatment can be useful to evaluate the risk of relapse after discontinuation of the therapy. Nevertheless, some patients affected by Graves' disease are TRAb-negative when a 1st generation assay is used. In this study we evaluated the diagnostic performance of a newly developed 2nd generation TRAb assay in 46 patients with Graves' disease with negative 1st generation TRAb assay results. A control group of 50 Graves' disease patients with positive 1st generation TRAb assay results, 50 patients with Hashimoto's thyroiditis and 50 patients with nodular goiter were also examined. Forty one of 46 patients with Graves' disease with negative 1st generation TRAb assay results showed a positive 2nd generation test. No differences were seen in control groups. In conclusion, the 2nd generation TRAb assay is more sensitive than the 1st generation test and should be used in clinical practice. Long-term prospective studies are needed to evaluate the prognostic role of the 2nd generation TRAb assay in Graves' disease.

:
Published Online: 2005-06-01
Published in Print: 2001-02-21

Copyright © 2001 by Walter de Gruyter GmbH & Co. KG

Articles in the same Issue

  1. Editorial
  2. Polymorphisms in the Apolipoprotein E Gene Regulatory Region in Relation to Coronary Heart Disease and Their Effect on Plasma Apolipoprotein E
  3. Further Characterization of Serum Amyloid A4 as a Minor Acute Phase Reactant and a Possible Nutritional Marker
  4. Determination of Human Angiotensin Converting Enzyme (ACE) Gene Polymorphisms in Erectile Dysfunction: Frequency Differences of ACE Gene Polymorphisms according to the Method of Analysis
  5. Simple Gas Chromatography Analysis of Faecal Butyrate: Application to Patients at Risk of Pouchitis
  6. Determination of Glycerol in Plasma by an Automated Enzymatic Spectrophotometric Procedure
  7. Clinical Applications of the 2nd Generation Assay for Anti-TSH Receptor Antibodies in Graves' Disease. Evaluation in Patients with Negative 1st Generation Test
  8. The Clinical Value of Microtransferrinuria and Microalbuminuria in the Prediction of Pre-eclampsia
  9. A Non-Icteric Cholecystectomized Patient with Recurrent Attacks of Right Epigastric Pain and Dilated Common Bile Duct – Do Liver Function Tests Predict Bile Duct Stones?
  10. Serum Lactate Dehydrogenase Isoenzyme 1 and Prediction of Death in Patients with Metastatic Testicular Germ Cell Tumors
  11. Annual Rhythmic and Non-Rhythmic Biological Variation of Magnesium and Ionized Calcium Concentrations
  12. Unit-Independent Reporting of Laboratory Test Results
  13. Analysis of Large and Small Samples of Biochemical and Clinical Data.
  14. Evaluation of Five Commercial Enzyme Immunoassays for the Detection of Human Cytomegalovirus-Specific IgM Antibodies in the Absence of a Commercially Available Gold Standard
  15. Alkaline Phosphatase Activity: New Assay for the Reflotron® System. Results of the Evaluation in Eight Clinical Laboratories
  16. Report on the 4th Estonian Summer School of Laboratory Medicine
  17. Laboratory-Related Measures of Patient Outcomes: An Introduction. Edited by Michael G. Bissell
  18. Report from the 50th Anniversary Congress of the Hungarian Society of Clinical Pathology and from the Executive Board Meeting of FESCC in Debrecen (Hungary)
  19. Report from the 8th Meeting of the Balkan Clinical Laboratory Federation
Downloaded on 28.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2001.007/html?lang=en
Scroll to top button